TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06689670: To Evaluate the Safety and Performance of INT001 in the Percutaneous Ablation of Liver Tumors: A Prospective, Single-arm, Single-center Clinical Study

Sponsor: inTumo Therapeutics, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 31 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06689670 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06689670 Rescue Dossier →